SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Keith Feral who wrote (123)5/29/2007 11:10:26 AM
From: Keith Feral of 418
 
I cleaned up the data results from the 3 trials. They are all pretty close to the trial results quoted by Adventrx. Hard to say which study is which.

Infusional 5FU / Leucovorin n = 187
Time to tumor progression - 4.4 months
22% response rate
14.1 months median survival

Irinotecan & infusional 5FU/Leucovorin n = 198
Time to tumor progression – 6.7 months
35% response rate
17.4 months median survival

Eloxatin + 5FU/LV n = 267
Time to tumor progression – 8.7 months
45.2% response rate
19.4 months median survival

Eloxatin + Irinotecan n = 264
Time to tumor progression – 6.5 months
34% response rate
17.6 months median survival

Avastin plus IFL n = 402
Time to tumor progression - 10.6 month
44.8% response rate
20.3 months median survival

ILF (leucovorin/5FU and irinotecan)
Time to tumor progression - 6.4 months
34.8% response rate
15.6 months median survival

FOLFOX
Time to tumor progression - 8.8 months
38% response rate
18.6 months median survival

Oxaliplatin & Irinotecan
Time to tumor progression - 6.7 months
28% response rate
16.5 months median survival

Cofactor – phase 2 study US
Time to tumor progression – 5.3 months
35% response rate
15.1 months survival rate
No Side Effects – hematological or gastrointestinal

Cofactor – Various Second Line Treatment – phase 2 US
23.0 months median survival rate, n = 37
21.5 months Folfiri, n=109
20.6 months Folfox6, n=111

Leucovorin
Time to tumor progression – 4 months
21% response rate
11.7 months median survival

Cofactor – Xeolda Studies –nude mouse study
Cofactor, 5FU, Xeloda – 60 day survival
Xeloda only – 38 day survival
Xeloda & 5FU – 39 day survival
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News